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Abstract
Objectives—To examine the comparative fate of adipose-derived stem cells (ASCs) as well as
their impact on coronary microcirculation following either retrograde coronary venous or arterial
delivery.
Background—Local delivery of ASCs to the heart has been proposed as a practical approach to
limiting the extent of myocardial infarction. Mouse models of mesenchymal stem cell effects on
the heart have also demonstrated significant benefits from systemic (intravenous) delivery,
prompting a question about the advantage of local delivery. There has been no study addressing
the extent of myocardial vs. systemic disposition of ASCs in large animal models following local
delivery to the myocardium.
Methods—In an initial experiment, dose-dependent effects of ASC delivery on coronary
circulation in normal swine were evaluated to establish a tolerable ASC dosing range for
intracoronary delivery. In a set of subsequent experiments, an anterior acute myocardial infarction
(AMI) was created by balloon occlusion of the proximal left anterior descending (LAD) artery,
followed by either intracoronary (IC) or retrograde coronary venous (RCV) infusion of
107 111Indium-labeled autologous ASCs 6 days following AMI. Indices of microcirculatory
resistance (IMR) and coronary flow reserve (CFR) were measured before sacrifices to collect
tissues for analysis at 1 or 24 hours after cell delivery.
Address Correspondence to: Keith L. March MD, PhD, 1481 W 10th St., C3109, Veterans Affairs Medical Center, Indianapolis, IN
46202, Tel: (317) 988-4976, kmarch@iupui.edu.
NIH Public Access
Author Manuscript
Catheter Cardiovasc Interv. Author manuscript; available in PMC 2015 January 01.
Published in final edited form as:
Catheter Cardiovasc Interv. 2014 January 1; 83(1): E17–E25. doi:10.1002/ccd.24659.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Results—IC delivery of porcine ASCs to normal myocardium was well-tolerated up to a
cumulative dose of 14×106 cells (approximately 0.5×106 cells/kg). There was evidence suggesting
microcirculatory trapping of ASC: at unit doses of 50×106 ASCs, IMR and CFR were found to be
persistently altered in the target LAD distribution at 7 days following delivery, while at 10×106
ASCs, only CFR was altered. In the context of recent MI, a significantly higher percentage of
ASCs was retained at 1 hour with IC delivery compared to RCV delivery (57.2 ± 12.7% vs. 17.9 ±
1.6%, p=0.037) but this initial difference was not apparent at 24 hours (22.6 ± 5.5% vs. 18.7 ±
8.6%; p= 0.722). In both approaches, most ASC redistributed to the pulmonary circulation by 24
hours post-delivery. There were no significant differences in CFR or IMR following ASC delivery
to infarcted tissue by either route.
Conclusions—Selective intravascular delivery of ASC by coronary arterial and venous routes
leads to similarly limited myocardial cell retention with predominant redistribution of cells to the
lungs. Intracoronary arterial delivery of ASC leads to only transiently greater myocardial
retention, which is accompanied by obstruction of normal regions of coronary microcirculation at
higher doses. The predominant intrapulmonary localization of cells following local delivery via
both methods prompts the notion that systemic delivery of ASC might provide similarly beneficial
outcomes while avoiding risks of inadvertent microcirculatory compromise.
Keywords
adipose-derived stem cells; swine model; acute myocardial infarction; microcirculatory resistance;
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INTRODUCTION
Adipose-derived stem cells (ASCs) can be readily obtained in large numbers by minimally
invasive techniques for autologous use to promote repair and rescue of cardiac tissues
following myocardial injury. The potential therapeutic effects of ASC in promoting reduced
scarring and increased revascularization have been demonstrated in animal models of
myocardial infarction (MI), heart failure, and hindlimb ischemia (1). These clear benefits as
well as the potential for autologous use have led to early clinical trials in patients (2–3). The
beneficial outcomes in cardiovascular disease models appear to occur predominantly
through paracrine effects (4–6) as well as acceleration of neovascularization (7–8), rather
than via direct regeneration through differentiation of ASCs.
Various clinically feasible modalities for local cell delivery to treat acute MI (AMI) patients
include intracoronary (IC), retrograde coronary venous (RCV), endocardial injection, and
open-chest epicardial injection(9–12). It was recently shown that IC delivery of ASCs is
more effective than transendocardial delivery in increasing neovascularization(13). The
efficiency of stem cell retention following vascular delivery to the heart presumably depends
on sufficient cellular extravasation into surrounding myocardial tissues, as well as local
growth factor gradients and surface receptor interactions. However, the degree to which this
initial cellular localization is truly necessary for efficacy is not well understood in light of
the growing recognition of the role of distant paracrine actions in mediating stem cell
effects. To comparatively assess the efficiency as well as potential adverse consequences of
cell delivery, we conducted a series of studies in both normal and infarcted swine heart,
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evaluating the short-term fate and dose-dependent effects on microcirculation of ASCs
delivered into the vascular system by either a venous route (retrograde coronary venous),
which potentially averts microvessel sludging by cells which do not migrate out of the
vessel, or the more commonly employed arterial route (intracoronary).
METHODS
Overall Study Designs
Animal handling and care followed the recommendations of the National Institute of Health
guide for the care and use of laboratory animals. All protocols were approved by the animal
care and use committee at Indiana University School of Medicine. A series of three
experimental protocols was conducted: 1) a dose-escalation study for intracoronary delivery
involved three pigs; 2) a study of the effects of two doses of intracoronary ASC (or saline
control) on coronary vasculature in normal myocardium utilized twelve pigs; and 3) a study
of ASC biodistribution comparing IC and RCV local delivery methods involved fourteen
pigs. All pigs were Yorkshire domestic (25–35 kg) of mixed gender.
In the third protocol, animals received myocardial infarction by proximal left anterior
descending (LAD) artery occlusion as described below. Six days after ischemia, these
animals were randomly assigned to 2 groups: IC group (n = 7) and RCV group (n = 7).
Every animal in these treatment groups received 107 111Indium (In)-labeled autologous
ASCs six days following MI. Animals were then evaluated for cell distribution by γ-
counting of tissue samples and whole-body imaging 1 hour (n=8, 4 animals from each
group) and 24 hours (n=6, 3 animals from each group) after cell delivery. ASCs would be
able to survive and provide more benefits to damaged microvascular structure when given
between 3 to 7 days after MI(14–15).
Intracoronary Dose Escalation Study
Allogeneic porcine ASC was used for IC dose-escalation study, and 3 animals received a
series of increasing doses of ASC without making MI. An initial 300 U/kg heparin bolus
was administered with additional 100 U/kg heparin provided hourly. First for dose
escalation study in 3 swine, an angioplasty balloon was inflated at low pressure in the
proximal LAD artery just distal to the first septal perforator after coronary angiogram. A 10
ml volume of cells was infused over 45 seconds. Angioplasty balloon was deflated after 3
minutes. The dose was escalated at 1, 3, 10, 30, 100 × 106 with 30 minutes interval. A
coronary angiogram as well as left ventriculogram was obtained at 15 minutes following
each infusion. Images were acquired in order to measure LV wall motion and beats to fill up
distal LAD with contrast, and images were analyzed by using Phillips 2.01 LV analysis
software. LV ejection fraction (LVEF) was calculated using the centerline method. Mean
arterial pressure (MAP) and LV end-diastolic pressure (LVEDP) were measured before and
after each dose.
CFR and IMR Measurements of Left Anterior Descending Artery
After the gradual dose escalation study, 12 additional swine were randomized into 3 groups:
control group (n=4, 5% serum with 0.9% normal saline injection), low-dose group (n=4, 10
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× 106 ASC injection), and high-dose group (n=4, 50 × 106 ASC injection). To evaluate for
the occurrence and persistence of altered microcirculatory function after cell delivery, IMR
and CFR were measured using a pressure wire technique, in each pig at baseline, 1-hour post
delivery, and 7-day post delivery. After LAD engagement and coronary angiography, a
0.014 inch fiberoptic pressure–temperature sensor-tipped guidewire (Radi Medical Systems,
Uppsala, Sweden) was equalized to the guiding catheter pressure with the sensor positioned
at the ostium of the guiding catheter and positioned as distal as possible in the LAD.
Proximal aortic and distal intracoronary pressures were recorded simultaneously. Papaverine
5 mg was used as the hyperemic agent. The mean transit time at rest and during hyperemia
were recorded after rapid injection of 3 ml of room-temperature saline through the guiding
catheter. The hyperemic and resting mean transit times were repeated 3 times, and the mean
value was used for the analysis. Thermodilution-derived CFR was calculated as the resting
mean transit time divided by the hyperemic mean transit time(16). The IMR was defined as
simultaneously measured distal coronary pressure multiplied by the thermodilution-derived
hyperemic mean transit time [mm Hg seconds or units (U)]. The mean transit time at rest
and during hyperemia was measured with commercially available software (Radi Medical
Systems). After calibration of the pressure sensor at the guiding catheter tip, the wire was
placed into the distal 1/3 of the LAD, followed by infusion of 3 ml saline at room
temperature and measurement of transit time by thermodilution. This was repeated 3 times,
followed by injection of 5 mg papaverine to induce hyperemia, and an additional sequence
of 3 saline injections with thermodilution measurements conducted after confirming a distal
LAD pressure drop of >10 mmHg.
Delivery Methods
Intracoronary Delivery—Six days after MI, coronary angiography was repeated to assess
the LAD. An angioplasty balloon of equivalent size to the proximal LAD was inflated at low
pressure (2 atm) at the site of previous balloon inflation, and 107 111In-labeled cells (10 ml)
were delivered at a rate of 1.3 ml/min with alternating 3 minute infusions and 3 minute
periods of reperfusion upon deflation of the angioplasty balloon.
Retrograde Coronary Venous Delivery—Venous access was obtained via the internal
jugular vein. The coronary venous system was then cannulated using a novel, investigational
double-balloon catheter (Venomatrix, Inc. CA). This device is made of 2 catheters: a
proximal outer catheter with a large balloon (1.0 × 0.5 cm), and a distal inner catheter with a
smaller balloon (0.5 × 0.5 cm). The distal balloon was applied to minimize washout of
delivered cells into the systemic circulation via distal, low-resistance venovenous
anastomoses. First, the coronary sinus was engaged using the proximal catheter that has a
pre-curved tip for simple cannulation. Then the proximal catheter was advanced into the
proximal interventricular vein (AIV) using a 0.014-inch flexible guidewire. A coronary
sinus venogram was performed initially to delineate anatomy and provide a roadmap for
subsequent cannulations. Afterward, the distal catheter was pushed through the proximal
device and advanced into the mid-to-distal AIV. Catheter placement was confirmed
angiographically by injection of 1–2 mL of diluted non-ionic contrast agent into the AIV,
and proper positioning was confirmed by the presence of significant contrast blush in the
area of the myocardium between the 2 balloons. To achieve better delivery in a pre-defined
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myocardial area, the distance between the proximal and distal balloons was kept around 2.5
cm. Subsequently, 107 111-In labeled cells in 10 mL saline with 5% autologous porcine
serum were infused between the 2 balloons at 300 mm Hg over 15 seconds, and the 2
balloons were deflated after 5 minutes to achieve maximum local delivery. Continuous
hemodynamic monitoring was maintained during the whole procedure using a femoral
arterial sheath.
Tissue Harvesting and Measurement of Radioactivity
Animals were euthanized 1 hour and 24 hours after cell delivery by a lethal dose of
pentobarbital (65 mg/kg). The hearts were removed and placed on ice for processing. Each
heart was transversely sliced into 5 sections of 1.5- to 2.0-cm thickness along the apical-
basal axis before further subdividing into 8 wedge shaped pieces of approximately equal
dimensions. The distribution of the injected radioactive cells was assessed by qualitative
whole-body radioactive scans (Ecat Exact HR+PET scanner, 63 planes, 15.5-cm field of
view) with a resolution of 4.2 mm, and γ-counter (Packard Auto-Gamma Cobra II) was used
for further quantification of radioactivity of harvested tissue samples. Technetium-99 LV
perfusion images were coupled with 111In-labeled ASC images for direct visualization by
dual isotope SPECT images. Harvested tissue samples from various organs (lungs, heart,
liver, spleen, and kidneys, and musculoskeleton) and delivery system were measured and
corrected for whole organ weight where appropriate. Approximately 1g piece of tissue from
each organ was collected for measurements of radioactive counts. γ-count values of tissues
harvested 1 hour and 24 hours after each delivery were multiplied in each case by the total
weight of the respective organ, and γ-count percentages of each visceral organ was defined
as the ratio of the locally retained radioactivity to the total radioactivity placed in the
delivery device. γ-count percentages of 5 major organs (heart, lung, liver, kidney, and
spleen) were calculated by the ratio of the locally retained radioactivity to the sum of total
radioactivity of 5 major organs.
Statistics
Results are presented as mean ± SD. Data were compared using a Mann-Whitney U test and
1-way ANOVA test (GraphPad InStat software, San Diego, CA), with differences between
data sets considered significant if P < 0.05.
Animal Catheterization, Isolation and Labeling of Porcine Autologous ASC, and Myocardial
Infarction Model are found in the Detailed Supplemental Methods
RESULTS
Study Animals with Myocardial Infarction
Ventricular arrhythmias occurred during each coronary balloon occlusion. Cardioversion
was successful in all animals, but 5 animals died suddenly 30 minutes to 8 hours following
MI due to intractable VF. The volume of infarcted LV myocardium, which was derived by
multiplying the thickness of each section by the areas of infarction, was 22 ± 5% in the IC
group and 20 ± 4% in the RCV group (P=NS).
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LVEF decreased from above 60% to less than 40% following MI in both groups, with no
differences between groups (Fig. 1B). Heart rate 6 days after MI demonstrated no
differences between groups (105 ± 8 bpm in the IC group and 109 ± 8 bpm in the RCV
group, p=0.703). Systolic (110 ± 7mmHg in the IC group and 103 ± 8mmHg in the RCV
group, p=0.329) and diastolic blood pressure (72 ± 6mmHg in the IC group and 70 ±
7mmHg in the RCV group, p=0.659) showed no differences between groups. Fractional
shortening 6 days after MI showed no differences between groups (24.3 ± 4.1% in the IC
group and 23.8 ± 3.8% in the RCV group, p=0.769). LV-end diastolic diameter (LVEDD)
(3.32 ± 0.41cm in the IC group and 3.38 ± 0.37cm in the RCV group, p=0.512) and LV-end
systolic diameter (LVESD) (2.51 ± 0.35cm in the IC group and 2.57 ± 0.32cm in the RCV
group, p=0.487) 6 days after MI showed no differences between groups. Decreases in MAP
from baseline to day 6 were 62 ± 8 mmHg to 43 ± 6 mmHg in the IC group and from 61 ± 7
mmHg to 45 ± 5 mmHg in the RCV group. Serum troponin levels were similar 24 hours
after MI in both groups (1.27 ± 0.30 ng/mL in the IC group and 1.17 ± 0.36 ng/mL in the
RCV group, p=0.578).
Evaluation of Heart Function in Relation to Dose
Blood flow to the distal LAD, measured under fluoroscopy by counting the number of heart
beats required to fill this region of the vessel with contrast, was not changed at bolus doses
up to 10×106 ASCs (cumulative dose of 14 × 106 ASCs); however, further doses in the
escalation series of 30 × 106 ASC (cumulative dose 44 × 106 ASCs) and then 100 × 106
ASC injections (cumulative dose 144 × 106 ASCs) resulted in a sharp decrease in filling
time (Fig. 2). No significant changes in LV wall motion were revealed until administration
of the 100 × 106 dose, which caused hypokinesia at apical anterior wall. This dose also
caused a slight decrease in LVEF (results not shown), and induced VF.
Based on these observations, a subsequent analysis was performed comparing single bolus
IC administration of ASCs in three groups of swine. Doses administered were 10 × 106
ASCs (low dose), 50 × 106 ASCs (high dose) or vehicle control. Microvascular function and
LV contractility were analyzed with IMR, CFR, and by left ventriculogram. A significant
increase from baseline in IMR was noted 7 days after ASC delivery in the high-dose group
(11.0 ± 1.3 vs. 17.8 ± 3.2, p=0.04, respectively) (Fig. 3A). Significant decreases from
baseline in CFR were noted in both the low-dose and high-dose groups at 7 days after
delivery (Fig. 3B). There were no instances of VF and no significant changes in LVEDP or
LVEF (Fig. 3C) were noted in all 3 groups.
Distribution of ASC after IC and RCV Delivery following Myocardial Infarction
Representative planar γ-scan images demonstrate that 111In-labeled ASCs were present in
the LV wall 1 hour after either IC or RCV delivery to infarcted hearts (Fig. 4A). The
delivery system such as syringe and catheter was thoroughly evaluated for remaining
radioactivity after ASC delivery. An average of 13 ± 3% of labeled ASC was noted to
remain in the delivery system immediately following injection, and 45 ± 10% of delivered
ASCs were distributed among the 5 major organs: lung, heart, liver, kidneys and spleen. The
remaining 42 ± 12% was in the musculoskeletal system and circulating blood.
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Quantitative analysis of the delivery distribution expressed as a percentage of delivery to the
major thoracoabdominal organs at 1 hour after delivery demonstrated significantly higher
(p=0.037) initial myocardial retention with IC (57.2 ± 12.7%) than with RCV (17.9 ± 1.6%)
delivery (Fig. 4B). A greater portion of retained cells was detected in the lungs at one hour
after RCV delivery (75.3 ± 4.7%) compared to IC delivery (23.4 ± 12.4%). However, there
was no difference in percentage of retained cells in the myocardium at 24 hours after IC
(22.6 ± 5.5%) or RCV (18.7 ± 8.6%) delivery (Fig. 4C). An equivalent proportion of ASCs
was also detected in the lungs at 24 hours after either IC and RCV delivery (59.7 ± 4.1% and
71.7 ± 10.2%) (Fig. 4C).
A comprehensive sectioning of the hearts was performed to determine the cell distribution
within the myocardium with respect to infarct location. ASCs delivered by the IC method
distributed mainly to the LV anterolateral segment (25.6 ± 4.9%), apical segments (26.2 ±
6.1%), and anterior right ventricle (19.5 ± 5.3%). In contrast, ASCs delivered by the RCV
method distributed mainly to the atria (18.1 ± 5.7%), right ventricle (20.2 ± 6.3%), and
inferolateral segment of LV (29.8 ± 6.8%).
The relative tolerability of both delivery methods with respect to microcirculation post-MI
was equivalent. Both IMR (Fig. 5A) and CFR measurements (Fig. 5B) were similar between
the 2 groups at baseline, pre-ASC delivery (6 days after MI), and post-ASC delivery (1 hour
after cell delivery).
DISCUSSION
ASCs represent one of the most practical therapeutic cell candidates to augment vascular
growth and tissue repair, since ASCs can be readily isolated and harvested in large quantities
with a minimally invasive liposuction for autologous use. A number of mechanisms of
action may contribute to the therapeutic effects of ASCs, including secretion of angiogenic
and anti-apoptotic factors (4,7,17–19), transdifferentiation into cardiomyocytes (20–21) or
vascular cells (8,22–23), and promotion of endogenous repair by resident progenitor cells
both locally and at a distance(1). Critical paracrine effects of ASCs in the repair of ischemic
tissues have also been demonstrated in multiple studies (24–26). These effects may occur at
a distance, possibly even when ASCs become trapped in the lung (27). In complementary
studies, the key contribution of paracrine factors secreted by ASC was demonstrated by
knockdown of HGF synthesis which led to markedly reduced ability of ASC to promote
angiogenesis in ischemic muscle tissue(19), and systemic neutralization of SDF-1 activity,
which led to decreased blood flow recovery in ischemic tissue following ASC
administration.(17)
Although several studies regarding IC delivery of ASCs after MI have been conducted in
animals (13,28–30) and more recently in humans(2), there has been no consensus regarding
the optimal delivery method with regard to efficacy and safety. In this study, we initially
evaluated normal animals in order to sensitively identify effects of IC ASC delivery on the
coronary microcirculation. We observed that IC delivery of less than 14 × 106 ASCs did not
obstruct coronary artery flow in the target vessel of swine, while a dramatic increase in the
number of beats required to fill the distal LAD was observed after IC delivery of cumulative
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doses exceeding 44 × 106 ASCs, suggesting significant microvascular occlusion. To further
evaluate these effects, we compared microvascular integrity among a control group (vehicle
only), a low-dose group (10 × 106 ASCs), and a high-dose group (50 × 106 ASCs). An
increase in IMR at 7 days was observed after delivery of the high dose of cells, but not with
the lower dose.
Rigol et al (13) suggested that injecting cells into the coronary circulation was more
effective in neovascularization than direct myocardial cell injections, partially due to a
paracrine effect. Since IC or RCV deliveries both provide direct intravascular access and do
not require separate intramyocardial instrumentation, we elected to comparatively study
these techniques for the first time with regard to acute distribution of 111-In labeled ASCs to
visceral organs. While myocardial ASC retention in swine MI model was higher 1 hour after
IC delivery than RCV delivery, this difference was not apparent by 24 hours after delivery.
Distribution in major non-target organs at 24 hours was also similar for ASCs delivered by
either IC or RCV. Cells delivered at the optimal dose by either method had no remaining
impact on microvascular integrity after 7 days. Therefore, both IC and RCV methods appear
to be safe and similarly effective. This study may suggest that the comparative suitability of
each delivery modality may be related to the ischemic area. Delivery by IC resulted in ASCs
localizing mainly to the LV anterolateral segment, apical segments, and anterior right
ventricle; whereas RCV resulted in localization of ASCs to the atria, right ventricle, and
inferolateral segment of LV. It is possible that IC delivery could be more beneficial to
patients with anteroapical MI and RCV delivery method in patients with inferolateral
ischemia or MI. Recent delivery of bone marrow mononuclear cells using the RCV
approach has shown the tolerability of this approach in patients with refractory angina(10).
For many years, it has been widely presumed that enhancing localization of cells to direct
delivery to a target tissue would play an important role in promoting the beneficial effects of
the cells. This has been so because of the hypotheses that key cellular effects involve
transdifferentiation, fusion, or other mechanisms that require cellular proximity. Our study
reveals that only a limited fraction of ASC are retained locally following two approaches to
intravascular delivery to the myocardial microcirculation, much as we demonstrated
previously with peripheral blood mononuclear cells(14). Furthermore, inadvertent
intracoronary delivery of ASCs to normal myocardium is accompanied by induction of
microcirculatory abnormalities. Taken together with the progressive understanding that a
major mechanism of ASC therapeutic effects involve paracrine secretions by ASCs, and
recent findings that ASCs embolized within the lung following systemic venous infusion are
active in secreting therapeutic molecules(27,31), we speculate that intravenous delivery of
ASC may indeed confer benefits of cardiac protection while eliminating the potential for
disruptions in the coronary microcirculation
IC Delivery of cultured swine ASC is well-tolerated even in non-infarcted myocardium, up
to a cumulative dose of 14 million cells (approximately 0.5 million cells/kg). However, we
would suggest that higher doses be administered with particular caution to selectively
deliver ASC only to ischemically-threatened myocardium, in order to limit the possibility of
microvascular compromise and possible additional injury to border-zone tissue. Although
the organ distribution of ASC was similar 24 hours after either IC or RCV delivery method,
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the localization of ASCs within the heart differed. If these findings in the porcine heart
extend to humans, our findings may support selection of delivery techniques based on
desired distribution of cells.
There are a few limitations in this study. Since we observed the safety of IC delivery of ASC
up to 7 days, a long-term follow-up is warranted to verify the safety of delivered ASC.
Moreover, the persistence and distribution of ASCs after 24 hours must be investigated, as
well as the long-term safety and efficacy of either IC or RCV delivery. Finally, the results of
this study may only pertain to ASC and may not extrapolate to other types of MSC or stem/
progenitor cells derived from other tissues.
Conclusions
The observation of predominant redistribution of ASC to the pulmonary circulation within
24 hours following delivery to infarcted myocardium highlights the need for further
understanding about the relative beneficial contribution of localized vs. distant cells in the
context of infarction limitation. While many studies have focused on mechanisms operative
at a local level, these reports cannot exclude the possibility that many of the cellular
contributions to therapy are indeed-mediated by cells distant from the myocardium. Our
study provides a clear rationale for the exploration of the functional consequences of
intravenous delivery of ASC in models of AMI and ultimately in the clinical setting.
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Fig. 1.
Study animal with myocardial infarction. A) Extensive anteroseptal myocardial infarction
was created by occluding proximal left anterior descending artery for 45 minutes.
Myocardial infarction created by the coronary occlusion and reperfusion injury is delineated
with TTC staining in pale area outlined by solid white line. B) The left ventricular ejection
fraction (LVEF) was calculated before and 6 days after left anterior descending artery
occlusion. Average values were measured from 7 animals in each group. LVEF showed no
significant differences between the 2 groups before and after myocardial infarction.
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Fig. 2.
Normal myocardium model. As the cumulative number of adipose-derived stem cell (ASC)
injection was increased, the beats to fill distal left anterior descending artery (LAD)
increased at the same time. A large increase in the beats to fill distal LAD was seen between
30 × 106 ASC (a cumulative dose of 44 × 106 ASC) and 100 × 106 ASC (a cumulative dose
of 144 × 106 ASC) injections.
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Fig. 3.
Normal myocardium model. A) A significant increase from baseline in the index of
microcirculatory resistance (IMR) was noted only in the high-dose group 7 days after
adipose-derived stem cell (ASC) delivery (* p<0.05 vs. baseline). B) Significant decreases
from baseline in coronary flow reserve (CFR) were noted in the low-dose and high-dose
groups 7 days after ASC delivery (* p<0.05 vs. baseline), and the 7-day CFR was
significantly lower than 1-hour CFR only in the high-dose group (§ p<0.05 vs. 1-hr post
delivery). C) No significant left ventricular ejection fraction changes were noted before and
after ASC delivery in all 3 groups.
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Fig. 4.
Post-myocardial infarction model. A) Direct visualization by dual isotope SPECT images 1
hour after either intracoronary (IC) or retrograde coronary venous (RCV) delivery into
porcine heart. Distribution of 111In-labeled adipose-derived stem cells (ASCs) (white
arrows) is shown in left ventricular short axis view coupled with 99Tc left ventricular
perfusion images (red doughnut shaped ring). B) Significantly higher myocardial ASC
retention (57.2 ± 12.7% vs. 17.9 ± 1.6%, p=0.037, respectively) with significantly lower
lung ASC retention was noted 1 hour after IC delivery when compared to RCV delivery. C)
Myocardial ASC retention was similar between the 2 groups 24 hours after IC and RCV
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deliveries (22.6 ± 5.5% vs. 18.7 ± 8.6%, p=0.722, respectively) with the majority of ASCs
in the lung (59.7 ± 4.1% vs. 71.7 ± 10.2%, p=0.323, respectively).
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Fig. 5.
Post-myocardial infarction model. IMR (Fig. 5A) and CFR measurements (Fig. 5B) were
similar between the 2 groups at baseline, pre-ASC delivery (6 days after MI), and post-ASC
delivery (1 hour after cell delivery).
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